share_log

Eli Glezer Bought 4.6% More Shares In Singular Genomics Systems

Eli Glezer Bought 4.6% More Shares In Singular Genomics Systems

Eli Glezer 又购买了奇异基因组学系统4.6%的股份
Simply Wall St ·  2023/11/21 05:04

Whilst it may not be a huge deal, we thought it was good to see that the Singular Genomics Systems, Inc. (NASDAQ:OMIC) Founder, Eli Glezer, recently bought US$86k worth of stock, for US$0.43 per share. Although the purchase is not a big one, increasing their shareholding by only 4.6%, it can be interpreted as a good sign.

尽管这可能不是什么大问题,但我们认为很高兴看到Singular Genomics Systems, Inc.(纳斯达克股票代码:OMIC)创始人埃利·格莱泽最近以每股0.43美元的价格购买了价值8.6万美元的股票。尽管此次收购并不大,仅增加了4.6%的股权,但可以将其解释为一个好兆头。

Check out our latest analysis for Singular Genomics Systems

查看我们对奇异基因组学系统的最新分析

The Last 12 Months Of Insider Transactions At Singular Genomics Systems

Singular Genomics Systems 最近 12 个月的内幕交易

In fact, the recent purchase by Founder Eli Glezer was not their only acquisition of Singular Genomics Systems shares this year. Earlier in the year, they paid US$0.82 per share in a US$139k purchase. That means that even when the share price was higher than US$0.41 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. The only individual insider to buy over the last year was Eli Glezer.

实际上,创始人埃利·格莱泽最近的收购并不是他们今年唯一一次收购Singular Genomics Systems的股票。今年早些时候,他们以13.9万美元的价格收购了每股0.82美元。这意味着,即使股价高于0.41美元(最近的价格),内部人士也想购买股票。尽管自收购以来,他们的看法可能已经改变,但这至少表明他们对公司的未来充满信心。在我们看来,内部人士为股票支付的价格非常重要。通常,当内部人士以高于当前价格的价格购买股票时,我们对股票的感觉会更加乐观,因为这表明即使价格更高,他们也认为股票物有所值。去年唯一买入的内部人士是埃利·格莱泽。

Eli Glezer purchased 420.00k shares over the year. The average price per share was US$0.77. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Eli Glezer在过去一年中购买了42.0万股股票。每股平均价格为0.77美元。下图显示了去年的内幕交易(公司和个人)。如果您想确切地知道谁售出、售价多少、何时出售,只需点击下图即可!

insider-trading-volume
NasdaqGS:OMIC Insider Trading Volume November 21st 2023
纳斯达克:2023 年 11 月 21 日的 omic 内幕交易量

Singular Genomics Systems is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Singular Genomics Systems并不是业内人士唯一买入的股票。对于那些喜欢寻找中奖投资的人来说,这份最近有内幕收购的成长型公司的免费名单可能只是门票。

Insider Ownership Of Singular Genomics Systems

奇异基因组学系统的内部所有权

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Singular Genomics Systems insiders own 15% of the company, worth about US$4.7m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

许多投资者喜欢检查公司有多少股份由内部人士拥有。较高的内部人所有权通常会使公司领导层更加关注股东的利益。从我们的数据来看,奇异基因组系统内部人士似乎拥有该公司15%的股份,价值约470万美元。总的来说,这种所有权水平并不那么令人印象深刻,但肯定总比没有好!

So What Does This Data Suggest About Singular Genomics Systems Insiders?

那么,这些数据对奇异基因组学系统内部人士有何启示呢?

The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that Singular Genomics Systems insiders are reasonably well aligned, and optimistic for the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Singular Genomics Systems. Our analysis shows 5 warning signs for Singular Genomics Systems (1 makes us a bit uncomfortable!) and we strongly recommend you look at these before investing.

最近的内幕收购令人振奋。对去年交易的分析也给了我们信心。但另一方面,该公司在去年出现了亏损,这使我们有些谨慎。尽管内部人所有权的总体水平低于我们希望看到的水平,但交易历史表明,Singular Genomics Systems内部人士的看法相当一致,对未来持乐观态度。除了了解正在进行的内幕交易外,识别奇异基因组学系统面临的风险也是有益的。我们的分析显示,奇异基因组学系统有5个警告信号(1让我们有点不舒服!)我们强烈建议您在投资之前先看看这些。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,来看看这份有趣的公司的免费清单吧。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发